Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical
syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is
now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control
has not been studied in this population. Catheter ablation and antiarrhythmic drugs are
rhythm control therapies that have been used for treatment of AF without HF or HF with
reduced systolic function but have not been widely applied in HFpEF. No controlled
comparative evaluation has been performed in HFpEF.
The introduction of wireless pulmonary artery hemodynamic monitoring has permitted
optimization of HF therapy in patients with chronic HF with reduced and preserved EF.
Reduction in HF hospitalizations has been observed in post hoc analyses of HFpEF patients but
has not been systematically applied in AF patients with HFpEF.
In this study, we propose to study both rhythm control and optimized HF therapeutic
approaches in an AF with HFpEF study population in a pilot study using a sequential two phase
randomized controlled clinical trial design.